Voluntary Licensing: Optimizing Global Efforts And Measuring Impact, I-MAK/ITPC

17 Sep 2012
View Resource

For the past decade, pharmaceutical companies have increasingly used voluntary licenses to allow generic production of patented antiretroviral drugs for People Living with HIV/AIDS in poor countries. However, these licenses have not been pursued optimally from a public health standpoint. This paper will comment on the current efforts of global health institutions and propose a path forward to ensure that voluntary licenses are pursued in a strategic, access-maximizing manner.

Partner with us now to build
a more just and equitable
medicine system for all.